I. Overview of the ESMO 2025 Guideline
In August 2025, ESMO officially released the Early and locally advanced non small cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow up, published in the top oncology journal Annals of Oncology. This is the first comprehensive update since the 2017 version and provides an extremely authoritative reference for oncologists worldwide.
Lung cancer has the highest incidence and mortality of all malignancies globally. Each year, there are more than 2.2 million new cases and over 1.8 million deaths, making lung cancer the leading cause of cancer-related death in both men and women. Non-small-cell lung cancer (NSCLC) accounts for approximately 80-85% of all lung cancer patients. Against this serious background, the release of the 2025 guideline injects new scientific momentum into clinical practice, with the update on biomarker testing strategies being particularly critical.
II. Interpretation of Key Guideline Updates
2.1 Biomarker Testing: From “Optional” to “Essential”
The 2025 guideline makes a milestone strategic adjustment regarding biomarker testing. The guideline explicitly states that biomarker testing is essential for treatment decision in patients with stage IB-III NSCLC.”
This recommendation extends molecular testing from its previous focus on patients with advanced disease to early-stage, resectable cases. The core objective is to identify driver gene mutations and provide a scientific basis for personalised precision treatment. The guideline also emphasises that the feasibility of biopsy and the diagnostic approach should be determined by a multidisciplinary team based on patient and tumour characteristics.
Regarding the specific testing strategy, the guideline clearly recommends that genetic testing be performed before surgical decision-making, and that it should at least cover EGFR and ALK. This “testing upfront” concept has profound clinical significance for the precise stratification and personalised treatment of early-stage NSCLC – the timeliness and accuracy of test results directly determine the choice of subsequent adjuvant therapy.
2.2 Therapeutic Breakthroughs in Driver-Oncogene Positive Early-Stage NSCLC
The 2025 guideline integrates evidence from multiple major clinical studies to establish a clear precision treatment pathway for patients with driver-oncogene-positive early-stage NSCLC.
EGFR-mutated positive patients: Based on the landmark ADAURA trial, postoperative adjuvant osimertinib for three years has become the global standard of care for patients with EGFR exon 19 deletions or exon 21 L858R mutations. The ADAURA trial is an international, multicentre, randomised, controlled phase III study evaluating the efficacy and safety of adjuvant osimertinib in patients with completely resected stage IB-IIIA EGFR-mutated NSCLC. The study showed that osimertinib significantly improved both disease-free survival and overall survival compared with placebo, establishing osimertinib as the new standard of care for this population. However, exploratory analyses of the ADAURA trial indicated that approximately 36% of early treatment discontinuations were driven by adverse events, and another 31% were due to patient decision. This finding highlights the need for accurate baseline testing before treatment to ensure that targeted therapy is given to patients who can derive sustained benefit.
ALK-positive patients: Based on the ALINA trial, postoperative adjuvant alectinib for two years is now the standard of care. In the primary analysis of the phase III randomised open-label ALINA trial, alectinib showed a marked disease-free survival benefit in the stage II-IIIA population, with a hazard ratio of 0.24. Updated data from the ALINA trial presented at the ESMO 2025 congress showed that after ≥3 years of follow-up, the DFS benefit of alectinib remained “sustained and clinically meaningful,” with a hazard ratio of 0.36 in the stage II-IIIA population. The latest reported 4-year overall survival rate reached 98.4%, the 4-year DFS rate was 75.5%, and central nervous system DFS was also improved, with no new safety signals. These robust data further establish adjuvant alectinib as the standard of care after resection of ALK-positive NSCLC and underscore the value of accurate testing to identify such patients.
Choice of testing method: The 2025 ESMO guideline explicitly lists multiplex RT-PCR panel assays alongside RNA-based NGS, IHC, and FISH as one of the recommended technical approaches for ALK fusion detection. This indicates that the guideline’s core requirement is to perform testing to guide clinical decisions, rather than to mandate a specific testing platform. For RT-PCR products focused on EGFR and ALK detection, this flexible testing strategy provides a strong guideline-based justification for their use in clinical practice.
III. Precision Testing Technical Solutions
The 2025 guideline moves testing forward to the pre-surgical decision-making stage, which raises the bar for assay accuracy, sensitivity, and accessibility. The two RT-PCR-based detection products described below align precisely with the guideline’s requirements from a technical perspective.
3.1 EGFR Mutation Detection Kit – Enhanced ARMS Technology Platform
Core technology: Enhanced ARMS technology enables specific amplification of low-abundance mutant sequences against a high wild-type background
Three technical safeguards:
-Enhanced ARMS → improves mutation recognition
-Enzymatic enrichment → digests wild-type background and enriches mutant sequences
-Temperature blocking → suppresses non-specific amplification
Performance: Sensitivity of 1% mutant allele frequency
Contamination control: Built-in internal control + UNG enzyme prevent contamination
Turnaround time: Closed-tube operation, approximately 120 minutes
Sample compatibility: Tissue/liquid biopsy samples → addresses “testing upfront” requirement
Coverage: 45 mutations in EGFR exons 18-21, precisely matching guideline-highlighted regions (exon 19 deletions and exon 21 L858R)
Clinical use: Directly guides EGFR-TKI therapy
3.2 MMT EML4-ALK Fusion Detection Kit – RNA-Based Fusion Detection Solution
-Technology platform: RNA-based RT-PCR – offers inherent advantages over DNA-based methods for fusion detection
-RNA-based advantage: Directly detects expressed fusion transcripts, effectively avoiding false negatives
-Study evidence: In low-abundance ALK fusions, RT-PCR is significantly more reliable than DNA-based tests
-Sensitivity: Detects fusions down to 20 copies per reaction
-Coverage of variants: Covers 12 common EML4-ALK fusion variants (including variant 1 ~33%; variants 3a/3b together ~29%)
-Operation & contamination control: Closed-tube, ~120 minutes; built-in process controls + UNG enzyme prevent false results
-Instrument compatibility: Compatible with various mainstream real-time PCR instruments
-Guideline alignment: Highly consistent with the ESMO guideline
IV. Consistency Between the Assays and the Guideline Recommendations
The two detection products are highly consistent with the ESMO 2025 Early and locally advanced non small-cell lung cancer guideline in the following key dimensions:
V. Conclusion
The ESMO 2025 early-stage NSCLC guideline ushers in a new era of precision diagnosis and treatment, centered on “testing upfront, precise targeting, and treatment optimisation.” The EGFR Mutation Detection Kit and MMT EML4-ALK Fusion Detection Kit meet the guideline’s requirements for targets, timing, and accuracy through distinct technical paths.
The EGFR kit uses enhanced ARMS technology for high-sensitivity detection of targeted mutations in limited samples, supporting both tissue and liquid biopsy to enable “testing upfront.”
The ALK kit is based on RNA-based RT-PCR, offering advantages over DNA methods for fusion detection, aligning with ESMO’s recommendation of multiplex RT-PCR panels for ALK testing.
Together, these two products form a precision testing solution compliant with the ESMO 2025 guideline, supporting personalised adjuvant therapy for early-stage NSCLC.
References:
- Zer A, Ahn M-J, Barlesi F, et al. Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36(11):1245-1262. doi:10.1016/j.annonc.2025.08.003
Post time: May-06-2026